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Background: We explore the pattern of late recurrence (LR) in solitary fibrous tumor (SFT), focusing on
histopathologic characteristics, clinical presentation and patients (pts) outcome.
Methods: Clinical records of all pts with confirmed pathologic diagnosis of SFT treated at our Institution from 2005
to 2011 were reviewed. We analysed the data of pts who relapsed ≥10 years after initial diagnosis.
Results: A total of 14 pts were identified. The primary site of origin was pleura (5 pts), pelvis (4 pts), head and neck
(3 pts) and retroperitoneum (2 pts). Primary tumor was a typical SFT in 5 and a malignant SFT in 7 out of 12 pts
whose tumor tissue was available for revision. The median time to first recurrence was 12 years (range 10–23). The
first relapse was local in 11 cases, distant in 3. Five pts later developed distant metastases. Four out of 5 cases of
typical SFT developed distant metastases in spite of their initial benign aspect. No patient was disease-free at the
time of the analyses.
Conclusion: Our series suggests that LR can occur in SFT and some cases can behave aggressively even in the
absence of any primary morphologic evidence of malignancy. A prolonged follow-up may be advisable.
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Solitary fibrous tumor (SFT) is a rare soft tissue neoplasm,
with an incidence of about 0,2/100.000/years. It was called
“haemangiopericytoma” by Stout and Murray in 1942.
However, the term “SFT” had been introduced by
Klemperer and Rabin in 1931, being regarded as a kind of
pleural mesothelioma [1]. A consensus on the overlap be-
tween haemangiopericytoma and SFT was then developed
in the ‘90s [2] (though the 2002 WHO “blue books” still
retain the two labels separately at least for some anatomical
locations) [3,4]. In practice, haemangiopericytoma and
SFT are the same entity, whatever their site of origin,
and the former term is currently abandoned (the
haemangiopericytoma-like histological pattern being a
non-specific feature shared by many neoplasms) [5].
In this regard, in the last WHO classification of bone
and soft tissue sarcoma SFT will be a separate nosological* Correspondence: gbaldi80@gmail.com
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reproduction in any medium, provided the orentity, the term haemangiopericytoma will be deleted and
SFT will be classified as “typical” or “malignant” based on
number of mitosis, cellular atypia, presence of necrosis
and hypercellularity [6].
The anatomical origin of SFT is almost ubiquitous, as
for soft tissue sarcomas in general. Indeed, SFT was
originally described in the pleura and then thought to
originate from serosal surfaces [5,7]. Finally, it was
reported in a set of other anatomical locations, going
from the meninges to soft tissues [8,9].
SFTs are classified in “typical” and “malignant” based on
the mitotic count (< and ≥4/10 high-power microscopic
fields, respectively), the presence of necrosis and nuclear
polymorphism. However, a strong correlation between
morphology and clinical course is lacking, so that, as of
today, there is no way to predict the outcome of a SFT
based on its pathologic features.
Indeed, we need such prognosticators, since SFT runs a
malignant course at least in 15-30% of cases [8,9]. Further-
more, SFTs can rarely show an abrupt transition from
conventional SFTs to high-grade sarcoma, also calledd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are aggressive soft tissue sarcomas [10].
Relatively few published series about SFT [11-19] are
available. In general, they prove complete surgical resec-
tion, whenever possible, associated with a favourable long-
term survival rate as opposed to incomplete excision.
Late recurrences are one of the clinical characteristics
of SFT’s [20-27]. Therefore, we decided to search our
institutional database and we found 14 SFT patients
who relapsed after ≥10 years from first complete surgery
and received medical treatment for the disease. This
paper reports on these patients.
Patients and methods
Clinical records of all patients with the diagnosis of SFT
who were treated at the Cancer Medical Department
of our institution from 2005 to 2011 were reviewed
retrospectively. We looked for patients who had relapsed
after ≥10 years from initial diagnosis, irrespective of where
primary tumor surgery was performed.
In addition, in order to estimate the frequency of late
relapses in this histological sarcoma subtype, we also
searched the institutional surgical database for all cases
of SFT surgically treated from 1995 to 2002. The
number of late relapses is provided in this series, while
the analysis of the clinical presentation and outcome of
relapses is confined to patients treated at our institution.
We selected only patients with initial complete surgery.
We reviewed all initial surgical reports, applying current
criteria for quality of surgery. Excisions were classified
according to the closest surgical margin, defining as R1
those with microscopically infiltrated margins and R0
those with microscopically negative margins.
In 12 cases, the first pathologic diagnosis was subse-
quently confirmed by experienced pathologists specialized
in sarcomas. In 2 cases (case 3 and 14), primary tumor
tissue was unavailable for review due to the long time
interval. In all cases, we had a pathologic diagnosis of re-
lapse (either following surgical excision or biopsy). Review
of the initial tumor was made on tumor tissue samples
from primary surgery in all cases. With regard to relapses,
tissue was available for all patients but 7, for whom fine
needle aspiration cytology (FNAC) was done (case 2, 3, 9,
10 and 14 for first relapses, and case 5, 7 and 14 for second
relapses: see Table 1). In 9 cases, unstained sections were
available in addition to hematoxilin/eosin (HE), so that the
morphologic diagnosis was complemented with CD34/bcl2
in 3 cases, CD34/Ki-67 in 3, CD34 in 2. In all 14 cases op-
erated on at our institution (9 at first surgery and 5 at re-
lapse), we assessed CD34 (clone NCL-L-END, Novocastra;
1:200), bcl (Clone 124; DakoCytomation; 1:500), CD99
(clone MIC2-12E7; Dako; 1:200) and Ki-67 (clone MIB-1;
Dakocytomation; 1:200), using Ultra Vision Quanto detec-
tion System HPR (Termo Scientific) according tomanufacturer’s protocol and antigen retrieval (60 at 95°C
5 mM citrate buffer ph 6 for the first three Abs and 150 at
95°5 mM citrate buffer ph6 for Ki-67). All cases were re-
classified according to the updated criteria for the diagnosis
of SFT, used at the time of the analyses [4,6,10,28].
Type and timing of follow up examinations varied among
different Institutions. In the majority of patients, however,
total body CT-scan were repeated every six months until
the fifth year after the primary excision. Then, X-ray and/or
abdominal ultrasound (on the basis of the site of the
primary tumor) was repeated every year and CT scan was
repeated to confirm recurrence.
Time to first recurrence was defined as the interval
between the excision of the primary tumor and the time of
first relapse (local and/or metastatic), detected and/or
confirmed by CT-scan. We estimated median OS from the
date of diagnosis and from the date of first relapse until
death from any cause, using the Kaplan-Meier method [29].
This retrospective case series analysis was approved by
the Institutional Ethics Committee.
Results
Patient characteristics are displayed in Table 1.
A total of 9 SFT patients were identified in the institu-
tional surgical database as having had a relapse at an
interval of ≥10 years from primary treatment. Only 3 of
them are included in this analysis. The number of
patients in this database is 83, so the rate of late relapse
in our series is 10%.
A total of 14 patients relapsing ≥10 years after complete
surgical resection of the primary tumor were identified
amongst all soft tissue sarcoma patients treated at our
institution.
The primary site of origin was pleura in 5 patients,
pelvis in 4, head and neck in 3 (orbital region, ethmoid,
maxillary region), retroperitoneum in 2. No patient had
a meningeal presentation, probably due to the referral
pattern of our institution.
All patients had extra-compartimental disease. Three
patients received adjuvant radiotherapy (RT), with a
dose ranging from 45 to 60 Gy. No patient was treated
with adjuvant chemotherapy.
The median time to first recurrence was 12 years
(range: 10–23 years). Ten patients recurred locally
without metastatic disease, 1 patient experienced both local
and distant relapse, 3 patients had a distant recurrence
without local relapse.
The 3 patients with distant recurrence only had previ-
ously received adjuvant RT, as opposed to no patient
among those with local relapses.
Among 11 patients who recurred locally (70% of the
cases in the current series), 9 were re-treated with surgery,
consisting in a macroscopic complete excision in all cases.
Postoperative RT was added in 3 cases.
Table 1 Patient characteristics and pathological/clinical findings
Patient Gender Age atdiagnosis Primary site Histology
Type of surgery
(R0/R1/R2)
Years first
relapse
Pattern of
relapse
First relapse
surgery
Histology Years second
relapse
Pattern of
relapse
Second relapse
surgery
Histology Status
last FU
1 M 52 pelvis MSFT R1 10y local Y MSFT 2y local Y MSFT DOD
2 M 28 head and neck MSFT R1 12y mts N MSFT* 1y mts N NA DOD
3 M 48 pleura NA R1 11y mts N MSFT* 1y mts N NA LFU
4 M 31 pelvis MSFT R1 10y local Y MSFT 0y local Y MSFT AWD
5 M 61 pelvis MSFT R1 11y local Y MSFT 2y mts N MSFT* DOD
6 F 36 pleura SFT R1 10y local Y MSFT 3y local Y MSFT LFU
7 F 66 pelvis MSFT R1 11y local Y MSFT 1y mts N MSFT* LFU
8 F 27 head and neck MSFT R1 16y local Y MSFT 11y local Y MSFT AWD
9 F 46 retroperitoneum SFT R1 13y mts N PDSFT* 1y mts N NA DOD
10 F 53 pleura SFT R1 12y local + mts N MSFT* 1y local N NA AWD
11 M 41 pleura MSFT R1 20y local Y MSFT 1y local N NA LFU
12 M 43 pleura SFT R1 13y local Y MSFT 1y local N NA DOD
13 M 58 head and neck SFT R1 10y local Y MSFT 6y mts Y MSFT DOD
14 M 41 retroperitoneum NA R1 23y local N MSFT* 1y mts N MSFT* DOD
*Histological diagnosis was performed by FNAC.
SFT, typical solitary fibrous tumor; MSFT, malignant solitary fibrous tumor; PDSFT, pleomorphic/dedifferentiated solitary fibrous tumor.
NA, not assessed; DOD, dead of disease; LFU, lost to follow-up; AWD, alive with disease.
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(3 with metastatic disease and 3 with local recurrence),
using a regimen with anthracycline and ifosfamide in 3
cases, high-dose continuous infusion ifosfamide in 2
cases, and cisplatin plus gemcitabine in 1 case. The best
response by RECIST was a partial response in 1 case
(treated with anthracycline plus ifosfamide), stable
disease in 3 cases (treated with anthracycline plus
ifosfamide and high dose ifosfamide in 2 cases) and pro-
gression in 2 cases (treated with anthracycline plus
ifosfamide and cisplatin plus gemcitabine respectively).
All patients initially treated with surgery on the first
local recurrence subsequently relapsed, either locally or
distantly in 6 and 3 cases, respectively.
Overall, the median number of relapses per patient all
over their clinical history was 2.8 (range: 2–4). Six out of
the 14 patients had more than one multifocal loco-
regional recurrence (Figure 1A-B-C-D), while 8 devel-
oped distant metastases during the course of the disease.
Median OS from the first diagnosis was 19 years.
Figure 2 displays the OS curves from relapse, for patients
with local recurrence only (Figure 2A) and for those with
metastatic ± local recurrence (Figure 2B).
At the time of the last follow-up, all patients had
evidence of disease: 7 had died of disease; 3 were alive
after 2, 5 and 14 years from the first relapse, respectively;
4 patients were lost to follow-up.Figure 1 CT scans of primary solitary fibrous tumor of the pleura (1A
after 12 years.On review of the 12 available primary tumor specimens,
SFT could be diagnosed as “typical” in 5 cases and
“malignant” (MSFT) in 7. Typical cases were collagen-rich
and hypocellular, had a very low mitotic rate, and lacked
any evidence of cytological atypia or features recalling
lipomatous or giant cell variants of SFT [5]. Four cases of
typical SFT at first diagnosis had evidence of metastases at
their first or second relapse.
All cases with a typical STF at the time of the primary
tumor showed aspects consistent with a MSFT at the
time of first and second relapse (Figure 3A-B-C-D), and
one patient (#9) whose liver metastasis was assessed
by FNAC had a dedifferentiated variant of SFT. This
tumor had a growth pattern closely resembling an
Ewing sarcoma/pPNET and recapitulating the recently
described round-cell dedifferentiated variant of SFT [10].
The correct diagnosis was rendered after ruling out a
diagnosis of pPNET by FISH analysis and reviewing the
primary tumor, as we already reported [30].
Discussion
We report on a series of 14 SFT patients who relapsed
after ≥10 years from initial diagnosis (median: 12 years)
and were treated thereof at our institution. Their median
OS from first diagnosis was 19 years and median OS
from first relapse was 8 years. Most patients (70%)
relapsed at the site of the primary tumor, with only 3-B) and the loco-regional relapse in mediastinal pleural (1C-D)
Figure 2 OS curves for patients with local recurrence only (2A)
and for those with metastatic ± local recurrence (2B).
Figure 3 Histopathological pattern of primary typical solitary fibrous
counterpart at relapse (3C) with high expression of Ki-67 (3D).
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local relapse. Six patients developed metastatic disease
only as late recurrence. No patient was cured, even
amongst those undergoing complete salvage surgery of
their first local recurrence. However, median OS was 8
years from relapse for all patients, with no major differ-
ence between locally relapsing and metastatic patients.
SFT represents a very rare disease and few studies are
available on the natural history of this tumor. In particular,
few cases of late relapses have been reported [20-26]. They
were mostly meningeal and pleural SFTs. Interestingly,
none of our patients had a meningeal origin, due to the re-
ferral pattern of our institution, and some had other than
pleural SFTs. Thus, we can conclude that late relapses are
a feature of SFT as such, i.e. they are not confined to men-
ingeal or pleural primary sites. This conclusion can be
made even on a limited series of patients, picked up at a
single institution on the basis of their unfavourable out-
come: thus, selection biases should be taken into account
when looking at this retrospective case series analysis.
It is well known that currently available pathologic
criteria for defining SFT “malignancy” are not satisfactory.
Our series confirms that SFTs can have an aggressive be-
haviour even in the absence of any morphologic evidence
of malignancy at onset. Interestingly, all our patients
showed signs of malignancy on relapse. This points to a
pathologic evolution which takes place in relapsing SFTs,
even when the relapse occurs late. In this sense, it is clear
that we need to refine criteria for SFT classification, al-
though available pathologic markers of malignancy clearly
correspond to a malignant attitude, having being recorded
in all our relapses.tumor (3A) with low expression of Ki-67 (3B) and the malignant
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sarcomatous evolution is seen, the malignant features of
SFT are consistent with a low-aggressiveness tumor. The
clinical counterpart of this conclusion is the long OS of
relapsing patients in our series, although the long previ-
ous disease-free interval is obviously a bias selecting
more indolent cases.
The patterns of relapse we observed emphasize the
inherent limitations of surgery in SFT, at least of some
typical anatomical sites. In fact, most of our patients first
recurred with a multinodular loco-regional relapse, and
metastases appeared later on. As observed by many [31],
high rates of local failure are found in epidural, pleural and
pelvic/retroperitoneal SFT, while local failure are much
rarer with SFT of soft tissues. In other words, SFT arising
in the pleural space, or retroperitoneum, or meninges, may
well tend to recur “locally” even when they have a benign
aspect and are apparently resected in a complete manner,
simply because of the inherent limitations of surgery in
such anatomical areas. Furthermore, “local” relapse in the
pleural space will inevitably lead to pleural dissemination,
thus to a pattern of spread which is very similar to a “meta-
static” extent. This explains why none of our patients have
been cured by salvage treatments, although relapses was
loco-regional only in 7. In part, this may also explain why
pathologic prognostic criteria are unsatisfactory, the relapse
being related to surgical inherent inadequacy much more
than to the tumor inherent aggressiveness. On the other
side, tumor relapse, whatever its cause, leads to the expres-
sion of pathologic markers of higher aggressiveness in all
patients. As said above, this is all the more meaningful in
our series, which selected late relapses.
Intriguingly, 3 out of 4 patients who were treated with
adjuvant radiation therapy did not recur locally while
experiencing late metastatic disease. The primary tumor
arose from pleural site in 2 cases and from
retroperitoneum in 1 case. The literature is inconclusive
in regard of adjuvant RT in SFT [32-35]. In a series of
11 SFT treated with definitive RT without surgery, no
patient had a local recurrence, and 9 were disease-free at 3
to 20 years from diagnosis [32]. Of course, RT can be
hardly advocated in a tumor which, at least retrospectively,
is “benign” in 70-80% of cases. However, prospective
studies on adjuvant RT in SFT could be conceived when
wide surgery is not feasible, as in meningeal, retroperiton-
eal and pleural presentations, and pathologic signs of
“malignancy” are present at the onset.
Our series suggests that late relapses can occur in
SFTs, even outside the meningeal setting. However, over-
all, they seem to be relatively rare. Thus, a prolonged
follow-up may be advisable. More importantly, clinicians
should be aware that new neoplastic lesions in a patient
with a history of SFT can represent a malignant relapse
with aggressive disease course, even though the primarytumor displayed “benign” features on pathologic assess-
ment. Current treatment strategies of relapse are clearly
insufficient, though reports of activity of new targeted
therapies are now available [36-39] so that the outlook
of the limited number of SFT patients who relapse may
be due to improve in the next future.
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